Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects
currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both
of these drugs are currently FDA approved as combination therapy for patients with Open-Angle
Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which
treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary
objective is to assess the tolerability of each drug.
Phase:
Phase 4
Details
Lead Sponsor:
Cornerstone Health Care, PA
Collaborator:
Allergan
Treatments:
Brimonidine Tartrate Brimonidine Tartrate, Timolol Maleate Drug Combination Brinzolamide